Tacrolimus 0.03% ointment treatment in exfoliative cheilitis: A randomised controlled clinical trial and monitoring blood concentration
Autor: | Hongmei Wang, Xiangjian Wang, Fanglong Wu, Mingjia Hu, Hongmei Zhou, Mei Lin, Jing He, Junjiang Liu, Liran Shi |
---|---|
Rok vydání: | 2020 |
Předmět: |
Cancer Research
medicine.medical_specialty Triamcinolone acetonide Administration Topical Tacrolimus Pathology and Forensic Medicine Ointments 03 medical and health sciences Exfoliative cheilitis 0302 clinical medicine Blood concentration medicine Humans In patient Oral mucosa business.industry 030206 dentistry Chronic inflammatory disorder Dermatology Clinical trial Treatment Outcome medicine.anatomical_structure Cheilitis Otorhinolaryngology 030220 oncology & carcinogenesis Periodontics Oral Surgery business Immunosuppressive Agents medicine.drug |
Zdroj: | Journal of Oral Pathology & Medicine. 50:251-259 |
ISSN: | 1600-0714 0904-2512 |
Popis: | BACKGROUND Tacrolimus has been used to treat various inflammatory skin diseases, but its safety for topical application on the oral mucosa is unknown. Exfoliative cheilitis (EC) is a chronic inflammatory disorder of the lips characterised by repeated scaling; it is difficult to manage. The aim of this study was to assess the efficacy and safety of tacrolimus 0.03% ointment as a topical treatment in patients with EC. METHODS In this randomised controlled clinical trial, 40 patients with EC were randomly assigned to receive either tacrolimus 0.03% ointment (experimental group, n = 20) or triamcinolone acetonide 0.1% cream (control group, n = 20) treatment for a 3-week period. Medication was administered in 3, 2 and 1 daily doses during the first, second and third weeks, respectively. The patients with complete healing were followed up for 3 months. The clinical outcomes were measured, including the scores regarding signs (scale, dryness, rhagades and swelling) and symptoms (rough, dry, pain, pruritus and burning sensation) at every visit. Blood concentrations of tacrolimus were assessed. RESULTS After the 3-week treatment, healing rates of scale in the experimental and control groups were 65% and 10%, respectively (P = .018). Improvement in all signs and two symptoms (rough, pruritus) was much greater in the experimental group (P |
Databáze: | OpenAIRE |
Externí odkaz: |